Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 166

1.

How to diagnose parkinsonian central pain?

Marques A, Attal N, Bouhassira D, Moisset X, Cantagrel N, Rascol O, Durif F, Brefel-Courbon C.

Parkinsonism Relat Disord. 2019 May 1. pii: S1353-8020(19)30220-2. doi: 10.1016/j.parkreldis.2019.04.025. [Epub ahead of print]

PMID:
31072757
2.

Reader response: Deep brain stimulation improves restless legs syndrome in patients with Parkinson disease.

Marques AR, Fantini ML, Durif F.

Neurology. 2019 Apr 30;92(18):868-869. doi: 10.1212/WNL.0000000000007411. No abstract available.

PMID:
31036574
3.

Impulse Control Disorders in REM Sleep Behavior Disorder.

Fantini ML, Durif F, Marques A.

Curr Treat Options Neurol. 2019 Apr 8;21(5):23. doi: 10.1007/s11940-019-0564-3. Review.

PMID:
30957207
4.

French validation of the questionnaire for Impulsive-Compulsive Disorders in Parkinson's Disease-Rating Scale (QUIP-RS).

Marques A, Vidal T, Pereira B, Benchetrit E, Socha J, Pineau F, Elbaz A, Artaud F, Mangone G, You H, Cormier F, Galitstky M, Pomies E, Rascol O, Derkinderen P, Weintraub D, Corvol JC, Durif F; DIGPD study group.

Parkinsonism Relat Disord. 2019 Jun;63:117-123. doi: 10.1016/j.parkreldis.2019.02.026. Epub 2019 Mar 4.

PMID:
30862454
5.

Compulsive eating behaviors in Parkinson's disease.

de Chazeron I, Durif F, Chereau-Boudet I, Fantini ML, Marques A, Derost P, Debilly B, Brousse G, Boirie Y, Llorca PM.

Eat Weight Disord. 2019 Jun;24(3):421-429. doi: 10.1007/s40519-019-00648-1. Epub 2019 Feb 4.

PMID:
30715681
6.

Wait and you shall see: sexual delay discounting in hypersexual Parkinson's disease.

Girard R, Obeso I, Thobois S, Park SA, Vidal T, Favre E, Ulla M, Broussolle E, Krack P, Durif F, Dreher JC.

Brain. 2019 Jan 1;142(1):146-162. doi: 10.1093/brain/awy298.

PMID:
30590514
7.

Suggestive association between OPRM1 and impulse control disorders in Parkinson's disease.

Cormier-Dequaire F, Bekadar S, Anheim M, Lebbah S, Pelissolo A, Krack P, Lacomblez L, Lhommée E, Castrioto A, Azulay JP, Defebvre L, Kreisler A, Durif F, Marques-Raquel A, Brefel-Courbon C, Grabli D, Roze E, Llorca PM, Ory-Magne F, Benatru I, Ansquer S, Maltête D, Tir M, Krystkowiak P, Tranchant C, Lagha-Boukbiza O, Lebrun-Vignes B, Mangone G, Vidailhet M, Charbonnier-Beaupel F, Rascol O, Lesage S, Brice A, Tezenas du Montcel S, Corvol JC; BADGE-PD study group.

Mov Disord. 2018 Dec;33(12):1878-1886. doi: 10.1002/mds.27519. Epub 2018 Nov 16.

PMID:
30444952
8.

Foreword.

Azulay JP, Durif F, Vidailhet M, Tranchant C.

Rev Neurol (Paris). 2018 Nov;174(9):579-580. doi: 10.1016/j.neurol.2018.10.001. No abstract available.

PMID:
30343834
9.

Naftazone in advanced Parkinson's disease: An acute L-DOPA challenge randomized controlled trial.

Corvol JC, Durif F, Meissner WG, Azulay JP, Haddad R, Guimarães-Costa R, Mariani LL, Cormier-Dequaire F, Thalamas C, Galitzky M, Boraud T, Debilly B, Eusebio A, Houot M, Dellapina E, Chaigneau V, Salis A, Lacomblez L, Benel L, Rascol O; French NS-Park/F-CRIN Network.

Parkinsonism Relat Disord. 2019 Mar;60:51-56. doi: 10.1016/j.parkreldis.2018.10.005. Epub 2018 Oct 4.

PMID:
30297210
10.

Longitudinal analysis of impulse control disorders in Parkinson disease.

Corvol JC, Artaud F, Cormier-Dequaire F, Rascol O, Durif F, Derkinderen P, Marques AR, Bourdain F, Brandel JP, Pico F, Lacomblez L, Bonnet C, Brefel-Courbon C, Ory-Magne F, Grabli D, Klebe S, Mangone G, You H, Mesnage V, Lee PC, Brice A, Vidailhet M, Elbaz A; DIGPD Study Group.

Neurology. 2018 Jul 17;91(3):e189-e201. doi: 10.1212/WNL.0000000000005816. Epub 2018 Jun 20.

11.

Impulse control disorders in Parkinson's disease patients with RLS: a cross sectional-study.

Marques A, Figorilli M, Pereira B, Derost P, Debilly B, Beudin P, Vidal T, Durif F, Fantini ML.

Sleep Med. 2018 Aug;48:148-154. doi: 10.1016/j.sleep.2018.02.004. Epub 2018 Mar 1.

PMID:
29913341
12.

Glucose dysregulation in Parkinson's disease: Too much glucose or not enough insulin?

Marques A, Dutheil F, Durand E, Rieu I, Mulliez A, Fantini ML, Boirie Y, Durif F.

Parkinsonism Relat Disord. 2018 Oct;55:122-127. doi: 10.1016/j.parkreldis.2018.05.026. Epub 2018 May 31.

PMID:
29866628
13.

Anatomical predictors of cognitive decline after subthalamic stimulation in Parkinson's disease.

Planche V, Munsch F, Pereira B, de Schlichting E, Vidal T, Coste J, Morand D, de Chazeron I, Derost P, Debilly B, Llorca PM, Lemaire JJ, Marques A, Durif F.

Brain Struct Funct. 2018 Sep;223(7):3063-3072. doi: 10.1007/s00429-018-1677-2. Epub 2018 May 7.

PMID:
29736590
14.

Impulse control disorders in Parkinson's disease.

Marques A, Durif F, Fernagut PO.

J Neural Transm (Vienna). 2018 Aug;125(8):1299-1312. doi: 10.1007/s00702-018-1870-8. Epub 2018 Mar 7. Review.

PMID:
29511827
15.

Behavioural outcomes of subthalamic stimulation and medical therapy versus medical therapy alone for Parkinson's disease with early motor complications (EARLYSTIM trial): secondary analysis of an open-label randomised trial.

Lhommée E, Wojtecki L, Czernecki V, Witt K, Maier F, Tonder L, Timmermann L, Hälbig TD, Pineau F, Durif F, Witjas T, Pinsker M, Mehdorn M, Sixel-Döring F, Kupsch A, Krüger R, Elben S, Chabardès S, Thobois S, Brefel-Courbon C, Ory-Magne F, Regis JM, Maltête D, Sauvaget A, Rau J, Schnitzler A, Schüpbach M, Schade-Brittinger C, Deuschl G, Houeto JL, Krack P; EARLYSTIM study group.

Lancet Neurol. 2018 Mar;17(3):223-231. doi: 10.1016/S1474-4422(18)30035-8.

PMID:
29452685
16.

Subacute corticobasal syndrome following internal carotid endarterectomy.

Marques A, Bourgois N, Vidal T, Ferrier A, Mathais S, Merlin C, Valla C, De Schlichting E, Jean B, Deffond D, Durif F.

Rev Neurol (Paris). 2018 Mar;174(3):157-161. doi: 10.1016/j.neurol.2017.06.017. Epub 2017 Nov 15.

PMID:
29153271
17.

Incobotulinum toxin A in Parkinson's disease with foot dystonia: A double blind randomized trial.

Rieu I, Degos B, Castelnovo G, Vial C, Durand E, Pereira B, Simonetta-Moreau M, Sangla S, Fluchère F, Guehl D, Burbaud P, Geny C, Gayraud D, Ory-Magne F, Bouhour F, Llinares E, Derost P, Marques A, Durif F.

Parkinsonism Relat Disord. 2018 Jan;46:9-15. doi: 10.1016/j.parkreldis.2017.10.009. Epub 2017 Oct 19.

PMID:
29102441
18.

Sleep and REM sleep behaviour disorder in Parkinson's disease with impulse control disorder.

Fantini ML, Figorilli M, Arnulf I, Zibetti M, Pereira B, Beudin P, Puligheddu M, Cormier-Dequaire F, Lacomblez L, Benchetrit E, Corvol JC, Cicolin A, Lopiano L, Marques A, Durif F.

J Neurol Neurosurg Psychiatry. 2018 Mar;89(3):305-310. doi: 10.1136/jnnp-2017-316576. Epub 2017 Oct 24.

PMID:
29066517
19.

Chronic pramipexole treatment induces compulsive behavior in rats with 6-OHDA lesions of the substantia nigra and ventral tegmental area.

Dardou D, Reyrolle L, Chassain C, Durif F.

Behav Brain Res. 2017 Aug 14;332:327-336. doi: 10.1016/j.bbr.2017.06.016. Epub 2017 Jun 17.

PMID:
28634107
20.

Striatal changes underlie MPEP-mediated suppression of the acquisition and expression of pramipexole-induced place preference in an alpha-synuclein rat model of Parkinson's disease.

Loiodice S, McGhan P, Gryshkova V, Fleurance R, Dardou D, Hafidi A, Nogueira da Costa A, Durif F.

J Psychopharmacol. 2017 Oct;31(10):1323-1333. doi: 10.1177/0269881117714051. Epub 2017 Jun 20.

PMID:
28631520
21.

Mapping of the brain hemodynamic responses to sensorimotor stimulation in a rodent model: A BOLD fMRI study.

Boussida S, Traoré AS, Durif F.

PLoS One. 2017 Apr 25;12(4):e0176512. doi: 10.1371/journal.pone.0176512. eCollection 2017.

22.

Comparison Between Automatic and Visual Scorings of REM Sleep Without Atonia for the Diagnosis of REM Sleep Behavior Disorder in Parkinson Disease.

Figorilli M, Ferri R, Zibetti M, Beudin P, Puligheddu M, Lopiano L, Cicolin A, Durif F, Marques A, Fantini ML.

Sleep. 2017 Feb 1;40(2). doi: 10.1093/sleep/zsw060.

PMID:
28364501
23.

Subthalamus stimulation in Parkinson disease: Accounting for the bilaterality of contacts.

Lemaire JJ, Pereira B, Derost P, Vassal F, Ulla M, Morand D, Coll G, Gabrillargues J, Marques A, Debilly B, Coste J, Durif F.

Surg Neurol Int. 2016 Nov 14;7(Suppl 35):S837-S847. eCollection 2016.

24.

Hallucinations in schizophrenia and Parkinson's disease: an analysis of sensory modalities involved and the repercussion on patients.

Llorca PM, Pereira B, Jardri R, Chereau-Boudet I, Brousse G, Misdrahi D, Fénelon G, Tronche AM, Schwan R, Lançon C, Marques A, Ulla M, Derost P, Debilly B, Durif F, de Chazeron I.

Sci Rep. 2016 Dec 1;6:38152. doi: 10.1038/srep38152.

25.

Intracerebral synthesis of glutamine from hyperpolarized glutamate.

Mazuel L, Schulte RF, Cladière A, Spéziale C, Lagrée M, Leremboure M, Jean B, Durif F, Chassain C.

Magn Reson Med. 2017 Oct;78(4):1296-1305. doi: 10.1002/mrm.26522. Epub 2016 Nov 8.

PMID:
27851869
26.

mGlu5 receptor antagonist blocks bromocriptine-induced conditioned place preference in bilateral mesolimbic-lesioned rat.

Ouachikh O, Chassain C, Pagès G, Durif F, Hafidi A.

Behav Brain Res. 2017 Jan 15;317:301-310. doi: 10.1016/j.bbr.2016.09.030. Epub 2016 Sep 13.

PMID:
27638036
27.

Pramipexole induced place preference after L-dopa therapy and nigral dopaminergic loss: linking behavior to transcriptional modifications.

Loiodice S, Winlow P, Dremier S, Hanon E, Dardou D, Ouachikh O, Hafidi A, da Costa AN, Durif F.

Psychopharmacology (Berl). 2017 Jan;234(1):15-27. doi: 10.1007/s00213-016-4430-7. Epub 2016 Sep 10.

PMID:
27614895
28.

French consensus procedure for assessing cognitive function in Parkinson's disease.

Dujardin K, Auzou N, Lhommée E, Czernecki V, Dubois B, Fradet A, Maltete D, Meyer M, Pineau F, Schmitt E, Sellal F, Tison F, Vidal T, Azulay JP, Welter ML, Corvol JC, Durif F, Rascol O; NS-Park network.

Rev Neurol (Paris). 2016 Nov;172(11):696-702. doi: 10.1016/j.neurol.2016.05.001. Epub 2016 Jun 16.

PMID:
27318613
29.

Personalized mapping of the deep brain with a white matter attenuated inversion recovery (WAIR) sequence at 1.5-tesla: Experience based on a series of 156 patients.

Zerroug A, Gabrillargues J, Coll G, Vassal F, Jean B, Chabert E, Claise B, Khalil T, Sakka L, Feschet F, Durif F, Boyer L, Coste J, Lemaire JJ.

Neurochirurgie. 2016 Aug;62(4):183-9. doi: 10.1016/j.neuchi.2016.01.009. Epub 2016 May 25.

PMID:
27236731
30.

A Phase 2A Trial of the Novel mGluR5-Negative Allosteric Modulator Dipraglurant for Levodopa-Induced Dyskinesia in Parkinson's Disease.

Tison F, Keywood C, Wakefield M, Durif F, Corvol JC, Eggert K, Lew M, Isaacson S, Bezard E, Poli SM, Goetz CG, Trenkwalder C, Rascol O.

Mov Disord. 2016 Sep;31(9):1373-80. doi: 10.1002/mds.26659. Epub 2016 May 23.

PMID:
27214664
31.

Randomized placebo-controlled trial of sodium valproate in progressive supranuclear palsy.

Leclair-Visonneau L, Rouaud T, Debilly B, Durif F, Houeto JL, Kreisler A, Defebvre L, Lamy E, Volteau C, Nguyen JM, Dily SL, Damier P, Boutoleau-Bretonnière C, Lejeune P, Derkinderen P.

Clin Neurol Neurosurg. 2016 Jul;146:35-9. doi: 10.1016/j.clineuro.2016.04.021. Epub 2016 Apr 27.

PMID:
27136096
32.

Quality of life in Parkinson's disease improved by apomorphine pump: the OPTIPUMP cohort study.

Drapier S, Eusebio A, Degos B, Vérin M, Durif F, Azulay JP, Viallet F, Rouaud T, Moreau C, Defebvre L, Fraix V, Tranchant C, Andre K, Courbon CB, Roze E, Devos D.

J Neurol. 2016 Jun;263(6):1111-9. doi: 10.1007/s00415-016-8106-3. Epub 2016 Apr 8.

PMID:
27060084
33.

Impact of Mood and Behavioral Disorders on Quality of Life in Parkinson's disease.

Rieu I, Houeto JL, Pereira B, De Chazeron I, Bichon A, Chéreau I, Ulla M, Brefel-Courbon C, Ory-Magne F, Dujardin K, Tison F, Krack P, Durif F.

J Parkinsons Dis. 2016;6(1):267-77. doi: 10.3233/JPD-150747.

PMID:
27003781
34.

A Placebo-Controlled Trial of AQW051 in Patients With Moderate to Severe Levodopa-Induced Dyskinesia.

Trenkwalder C, Berg D, Rascol O, Eggert K, Ceballos-Baumann A, Corvol JC, Storch A, Zhang L, Azulay JP, Broussolle E, Defebvre L, Geny C, Gostkowski M, Stocchi F, Tranchant C, Derkinderen P, Durif F, Espay AJ, Feigin A, Houeto JL, Schwarz J, Di Paolo T, Feuerbach D, Hockey HU, Jaeger J, Jakab A, Johns D, Linazasoro G, Maruff P, Rozenberg I, Sovago J, Weiss M, Gomez-Mancilla B.

Mov Disord. 2016 Jul;31(7):1049-54. doi: 10.1002/mds.26569. Epub 2016 Mar 15.

PMID:
26990766
35.

Profile of Neuropsychiatric Symptoms in Parkinson's Disease: Surgical Candidates Compared to Controls.

Lamberti VM, Pereira B, Lhommée E, Bichon A, Schmitt E, Pelissier P, Kistner A, Fraix V, Castrioto A, Esselink RA, Durif F, Krack P.

J Parkinsons Dis. 2016;6(1):133-42. doi: 10.3233/JPD-150698.

PMID:
26889631
36.

Nigrostriatal dopaminergic depletion increases static orofacial allodynia.

Dieb W, Ouachikh O, Alves S, Boucher Y, Durif F, Hafidi A.

J Headache Pain. 2016;17:11. doi: 10.1186/s10194-016-0607-z. Epub 2016 Feb 17.

37.

Metabolic, synaptic and behavioral impact of 5-week chronic deep brain stimulation in hemiparkinsonian rats.

Chassain C, Melon C, Salin P, Vitale F, Couraud S, Durif F, Kerkerian-Le Goff L, Gubellini P.

J Neurochem. 2016 Mar;136(5):1004-16. doi: 10.1111/jnc.13438. Epub 2015 Dec 21.

38.

Parkinson's disease: A risk factor for osteoporosis.

Malochet-Guinamand S, Durif F, Thomas T.

Joint Bone Spine. 2015 Dec;82(6):406-10. doi: 10.1016/j.jbspin.2015.03.009. Epub 2015 Oct 6. Review.

PMID:
26453100
39.

Impact of localisation of deep brain stimulation electrodes on motor and neurobehavioural outcomes in Parkinson's disease.

de Chazeron I, Pereira B, Chereau-Boudet I, Durif F, Lemaire JJ, Brousse G, Ulla M, Derost P, Debilly B, Llorca PM.

J Neurol Neurosurg Psychiatry. 2016 Jul;87(7):758-66. doi: 10.1136/jnnp-2015-310953. Epub 2015 Aug 21.

PMID:
26296870
40.

Proton MR Spectroscopy for Diagnosis and Evaluation of Treatment Efficacy in Parkinson Disease.

Mazuel L, Chassain C, Jean B, Pereira B, Cladière A, Speziale C, Durif F.

Radiology. 2016 Feb;278(2):505-13. doi: 10.1148/radiol.2015142764. Epub 2015 Aug 4.

PMID:
26237591
41.

Nigrostriatal dopaminergic depletion produces orofacial static mechanical allodynia.

Dieb W, Ouachikh O, Durif F, Hafidi A.

Eur J Pain. 2016 Feb;20(2):196-205. doi: 10.1002/ejp.707. Epub 2015 Apr 21.

PMID:
25899074
42.

Emergence of restless legs syndrome after subthalamic stimulation in Parkinson's disease: a dopaminergic overstimulation?

Marques A, Fantini ML, Morand D, Pereira B, Derost P, Ulla M, Debilly B, Lemaire JJ, Durif F.

Sleep Med. 2015 May;16(5):583-8. doi: 10.1016/j.sleep.2014.11.020. Epub 2015 Mar 3.

PMID:
25881920
43.

International validation of a behavioral scale in Parkinson's disease without dementia.

Rieu I, Martinez-Martin P, Pereira B, De Chazeron I, Verhagen Metman L, Jahanshahi M, Ardouin C, Chéreau I, Brefel-Courbon C, Ory-Magne F, Klinger H, Peyrol F, Schupbach M, Dujardin K, Tison F, Houeto JL, Krack P, Durif F.

Mov Disord. 2015 Apr 15;30(5):705-13. doi: 10.1002/mds.26223. Epub 2015 Mar 21.

PMID:
25809278
44.

Polymorphism of the dopamine transporter type 1 gene modifies the treatment response in Parkinson's disease.

Moreau C, Meguig S, Corvol JC, Labreuche J, Vasseur F, Duhamel A, Delval A, Bardyn T, Devedjian JC, Rouaix N, Petyt G, Brefel-Courbon C, Ory-Magne F, Guehl D, Eusebio A, Fraix V, Saulnier PJ, Lagha-Boukbiza O, Durif F, Faighel M, Giordana C, Drapier S, Maltête D, Tranchant C, Houeto JL, Debû B, Azulay JP, Tison F, Destée A, Vidailhet M, Rascol O, Dujardin K, Defebvre L, Bordet R, Sablonnière B, Devos D; Parkgait-II Study Group.

Brain. 2015 May;138(Pt 5):1271-83. doi: 10.1093/brain/awv063. Epub 2015 Mar 23.

45.

Social behavioral changes in MPTP-treated monkey model of Parkinson's disease.

Durand E, Petit O, Tremblay L, Zimmer C, Sgambato-Faure V, Chassain C, Laurent M, Pereira B, Silberberg C, Durif F.

Front Behav Neurosci. 2015 Feb 26;9:42. doi: 10.3389/fnbeh.2015.00042. eCollection 2015.

46.

Chronic pramipexole treatment increases tolerance for sucrose in normal and ventral tegmental lesioned rats.

Dardou D, Chassain C, Durif F.

Front Neurosci. 2015 Jan 6;8:437. doi: 10.3389/fnins.2014.00437. eCollection 2014.

47.

Progressive brain metabolic changes under deep brain stimulation of subthalamic nucleus in parkinsonian rats.

Melon C, Chassain C, Bielicki G, Renou JP, Kerkerian-Le Goff L, Salin P, Durif F.

J Neurochem. 2015 Mar;132(6):703-12. doi: 10.1111/jnc.13015. Epub 2015 Feb 12.

48.

Validation of a Psycho-Sensory hAllucinations Scale (PSAS) in schizophrenia and Parkinson's disease.

de Chazeron I, Pereira B, Chereau-Boudet I, Brousse G, Misdrahi D, Fénelon G, Tronche AM, Schwan R, Lançon C, Marques A, Debilly B, Durif F, Llorca PM.

Schizophr Res. 2015 Feb;161(2-3):269-76. doi: 10.1016/j.schres.2014.11.010. Epub 2014 Dec 4.

PMID:
25481345
49.

Neural substrates of levodopa-responsive gait disorders and freezing in advanced Parkinson's disease: a kinesthetic imagery approach.

Maillet A, Thobois S, Fraix V, Redouté J, Le Bars D, Lavenne F, Derost P, Durif F, Bloem BR, Krack P, Pollak P, Debû B.

Hum Brain Mapp. 2015 Mar;36(3):959-80. doi: 10.1002/hbm.22679. Epub 2014 Nov 19.

PMID:
25411130
50.

Increased risk of impulse control symptoms in Parkinson's disease with REM sleep behaviour disorder.

Fantini ML, Macedo L, Zibetti M, Sarchioto M, Vidal T, Pereira B, Marques A, Debilly B, Derost P, Ulla M, Vitello N, Cicolin A, Lopiano L, Durif F.

J Neurol Neurosurg Psychiatry. 2015 Feb;86(2):174-9. doi: 10.1136/jnnp-2014-307904. Epub 2014 Jul 8.

Supplemental Content

Support Center